CN100438778C - 一种耐缺氧抗疲劳的保健食品及其制备工艺 - Google Patents
一种耐缺氧抗疲劳的保健食品及其制备工艺 Download PDFInfo
- Publication number
- CN100438778C CN100438778C CNB200510002275XA CN200510002275A CN100438778C CN 100438778 C CN100438778 C CN 100438778C CN B200510002275X A CNB200510002275X A CN B200510002275XA CN 200510002275 A CN200510002275 A CN 200510002275A CN 100438778 C CN100438778 C CN 100438778C
- Authority
- CN
- China
- Prior art keywords
- vitamin
- standby
- taurine
- mesh sieves
- silica gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010021143 Hypoxia Diseases 0.000 title claims abstract description 15
- 235000013402 health food Nutrition 0.000 title claims description 18
- 230000002929 anti-fatigue Effects 0.000 title claims description 14
- 230000007954 hypoxia Effects 0.000 title claims description 14
- 238000002360 preparation method Methods 0.000 title abstract description 17
- 238000000034 method Methods 0.000 title abstract description 3
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 98
- 229960003080 taurine Drugs 0.000 claims abstract description 49
- 239000000463 material Substances 0.000 claims abstract description 43
- 239000011248 coating agent Substances 0.000 claims abstract description 10
- 238000000576 coating method Methods 0.000 claims abstract description 10
- 239000000853 adhesive Substances 0.000 claims abstract description 9
- 230000001070 adhesive effect Effects 0.000 claims abstract description 9
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 52
- 241001632410 Eleutherococcus senticosus Species 0.000 claims description 37
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 34
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 34
- 229930003451 Vitamin B1 Natural products 0.000 claims description 34
- 229930003471 Vitamin B2 Natural products 0.000 claims description 34
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 34
- 229960002477 riboflavin Drugs 0.000 claims description 34
- 239000003826 tablet Substances 0.000 claims description 34
- 229960003495 thiamine Drugs 0.000 claims description 34
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 34
- 235000010374 vitamin B1 Nutrition 0.000 claims description 34
- 239000011691 vitamin B1 Substances 0.000 claims description 34
- 235000019164 vitamin B2 Nutrition 0.000 claims description 34
- 239000011716 vitamin B2 Substances 0.000 claims description 34
- 235000019158 vitamin B6 Nutrition 0.000 claims description 34
- 239000011726 vitamin B6 Substances 0.000 claims description 34
- 229940011671 vitamin b6 Drugs 0.000 claims description 34
- 239000000843 powder Substances 0.000 claims description 33
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 30
- 239000000741 silica gel Substances 0.000 claims description 29
- 229910002027 silica gel Inorganic materials 0.000 claims description 29
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 26
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 26
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 26
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 26
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 21
- 238000002156 mixing Methods 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 20
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 20
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 19
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 18
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 18
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 16
- 235000009508 confectionery Nutrition 0.000 claims description 15
- 235000014101 wine Nutrition 0.000 claims description 15
- 238000001514 detection method Methods 0.000 claims description 14
- 108010011485 Aspartame Proteins 0.000 claims description 13
- 239000000605 aspartame Substances 0.000 claims description 13
- 235000010357 aspartame Nutrition 0.000 claims description 13
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 13
- 229960003438 aspartame Drugs 0.000 claims description 13
- 229920002472 Starch Polymers 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 239000008107 starch Substances 0.000 claims description 11
- 235000019698 starch Nutrition 0.000 claims description 11
- 235000000346 sugar Nutrition 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 10
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 10
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 10
- 244000246386 Mentha pulegium Species 0.000 claims description 9
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 9
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 9
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 9
- 235000001050 hortel pimenta Nutrition 0.000 claims description 9
- 238000006116 polymerization reaction Methods 0.000 claims description 9
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 9
- 229940013618 stevioside Drugs 0.000 claims description 9
- 235000019202 steviosides Nutrition 0.000 claims description 9
- 229930006000 Sucrose Natural products 0.000 claims description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 8
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 8
- 239000007921 spray Substances 0.000 claims description 8
- 229960004793 sucrose Drugs 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 235000020985 whole grains Nutrition 0.000 claims description 8
- 239000011734 sodium Substances 0.000 claims description 7
- 229920003149 Eudragit® E 100 Polymers 0.000 claims description 6
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 241000208340 Araliaceae Species 0.000 claims description 5
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 5
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 5
- 235000008434 ginseng Nutrition 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000000080 wetting agent Substances 0.000 claims description 4
- 229920003163 Eudragit® NE 30 D Polymers 0.000 claims description 3
- 244000068988 Glycine max Species 0.000 claims description 3
- 235000010469 Glycine max Nutrition 0.000 claims description 3
- 239000006189 buccal tablet Substances 0.000 claims description 3
- 239000007910 chewable tablet Substances 0.000 claims description 3
- 239000007938 effervescent tablet Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 235000013339 cereals Nutrition 0.000 claims description 2
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 claims description 2
- 238000007908 dry granulation Methods 0.000 claims description 2
- 239000007888 film coating Substances 0.000 claims description 2
- 238000009501 film coating Methods 0.000 claims description 2
- 238000009775 high-speed stirring Methods 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 238000005550 wet granulation Methods 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 3
- 229930195725 Mannitol Natural products 0.000 claims 3
- 239000000594 mannitol Substances 0.000 claims 3
- 235000010355 mannitol Nutrition 0.000 claims 3
- 239000000945 filler Substances 0.000 abstract description 12
- 239000000314 lubricant Substances 0.000 abstract description 10
- 239000002994 raw material Substances 0.000 abstract description 9
- 239000003795 chemical substances by application Substances 0.000 abstract description 7
- 230000006870 function Effects 0.000 abstract description 7
- 229940088594 vitamin Drugs 0.000 abstract description 6
- 229930003231 vitamin Natural products 0.000 abstract description 6
- 235000013343 vitamin Nutrition 0.000 abstract description 6
- 239000011782 vitamin Substances 0.000 abstract description 6
- 238000005516 engineering process Methods 0.000 abstract description 5
- 239000000284 extract Substances 0.000 abstract description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 239000007884 disintegrant Substances 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- -1 cupreol glycoside Chemical class 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- QJVXKWHHAMZTBY-GCPOEHJPSA-N syringin Chemical compound COC1=CC(\C=C\CO)=CC(OC)=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QJVXKWHHAMZTBY-GCPOEHJPSA-N 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- IKUQEFGEUOOPGY-UHFFFAOYSA-N Eleutheroside B1 Chemical compound COC1=CC=2C=CC(=O)OC=2C(OC)=C1OC1OC(CO)C(O)C(O)C1O IKUQEFGEUOOPGY-UHFFFAOYSA-N 0.000 description 2
- FFDULTAFAQRACT-OVUSVGQASA-N Eleutheroside D Chemical compound COC1=CC(C2C3C(C(OC3)C=3C=C(OC)C(O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=C(OC)C=3)CO2)=CC(OC)=C1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FFDULTAFAQRACT-OVUSVGQASA-N 0.000 description 2
- FFDULTAFAQRACT-MWBGVTEFSA-N Eleutheroside E Natural products COc1cc(cc(OC)c1O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)[C@@H]3OC[C@H]4[C@H]3CO[C@@H]4c5cc(OC)c(O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)c(OC)c5 FFDULTAFAQRACT-MWBGVTEFSA-N 0.000 description 2
- FFDULTAFAQRACT-JSGUJALWSA-N Eleutheroside E Chemical compound COC1=CC([C@@H]2[C@@H]3[C@H]([C@@H](OC3)C=3C=C(OC)C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=C(OC)C=3)CO2)=CC(OC)=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FFDULTAFAQRACT-JSGUJALWSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 2
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 102100031013 Transgelin Human genes 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- ZKNVDVVWFWMIOY-IVCZRNNFSA-N eleutheroside A Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5O[C@H](CC)[C@@H](O)[C@H](O)[C@H]5O)C(C)C ZKNVDVVWFWMIOY-IVCZRNNFSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 2
- QJVXKWHHAMZTBY-KSXIZUIISA-N syringin Natural products COc1cc(C=CCO)cc(OC)c1O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O QJVXKWHHAMZTBY-KSXIZUIISA-N 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 101100273639 Carassius auratus ccna1 gene Proteins 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- YYDFZHAEFGGSIC-UHFFFAOYSA-N Eleutheroside B1 Natural products COc1cc2C(=O)C=COc2c(OC)c1OC3OC(CO)C(O)C(O)C3O YYDFZHAEFGGSIC-UHFFFAOYSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000132519 Galactites Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000496 anti-anoxic effect Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 229930190029 eleutheroside Natural products 0.000 description 1
- 239000008769 eleutheroside Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- ZOLPMMWNCLHKPX-UHFFFAOYSA-N ligustrin Natural products CC1=CCC2C1C3OC(=C)C(=O)C3C(O)CC2=C ZOLPMMWNCLHKPX-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229940099429 polyoxyl 40 stearate Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- KOWMJRJXZMEZLD-UHFFFAOYSA-N syringaresinol Chemical compound COC1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(OC)C(O)=C(OC)C=3)CO2)=C1 KOWMJRJXZMEZLD-UHFFFAOYSA-N 0.000 description 1
- LVUPFEOCDSHRBL-UHFFFAOYSA-N syringaresinol Natural products COc1cccc(OC)c1C2OCC3C2COC3c4c(OC)cccc4OC LVUPFEOCDSHRBL-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种活性成分组分由刺五加提取物、牛磺酸和维生素所组成,并具有耐缺氧抗疲劳等功效的保健食品及其制备工艺,所述的保健食品所含的活性成分的组成为每单位制剂含刺五加提取物100mg、牛磺酸200mg、维生素B1 0.06mg、维生素B2 0.06mg和维生素B60.06mg。可用于缓解哺乳动物和人的疲劳及提高耐缺氧的能力。
Description
技术领域
本发明涉及一种耐缺氧抗疲劳的保健食品及其制备工艺。该保健食品的主要活性成分含有刺五加提取物、牛磺酸和维生素。本发明涉及制备所述保健食品的方法以及该产品的应用。
背景技术
疲劳是处于疾病和健康之间的一种亚健康状态,常常引起失眠、消化不良、高血压等疾病,对人类的危害极大。随着经济的高速发展,竞争激烈,生活节奏加快,疲劳正以更深的程度和更广的范围影响人类的健康。疲劳的人群往往出现力不从心、缺乏生活热情和乐趣等现象。
本发明以刺五加和牛磺酸为主要活性成分,研制除一种缓解疲劳、耐缺氧的功能食品。
刺五加的主要化学成分有刺五加甙A(Eleutheroside A,即β-谷甾醇葡萄糖甙),刺五加甙B(即紫丁香甙Syringin),刺五加甙B1(即6,8-二甲氧基香豆素-7-葡萄糖甙),刺五加甙(即乙基半乳糖甙),刺五加甙D和E(为二种不同构型的紫丁香树脂酚的葡萄糖甙)等。此外,尚含多糖及1-芝麻脂素(1-Sesamin)。
刺五加类似人参,具有调节机体紊乱的功能使之趋于正常的作用,有“适应原”样作用,能调节机体新陈代谢的机能,提高机体对有害刺激因子(如寒冷、灼热、过重、过度劳动、x线照射等)的非特异性抵抗力;能增强垂体-肾上腺皮质系统的功能,提高机体的适应性和耐受性,减低体内外多种致病因子对机体的损害。老年慢性病患者服刺五加制剂后,能增强体力,使衰弱、疲劳、食欲不振等症状消除或减轻,并有改善脑力活动及提高视力、听力的功效。临床上用于老年性衰弱,对体虚乏力、食欲不振、失眠多梦、神经官能症等有一定疗效。
药理研究表明,刺五加提取物有如下功效:
①有良好的抗疲劳作用,较人参显著,并能明显地提高耐缺氧能力;
②能增强机体非特异性免疫防卫能力,可使小鼠网状内皮系统吞噬功能显著增强,可使正常小鼠及带瘤小鼠脾脏重量增加,脾脏内巨噬细胞平均值明显增加;
③能促进抗体的形成;
④提高小鼠e玫瑰花结形成率;
⑤对家兔苯中毒及小鼠服用环磷酰胺所致的白细胞减少均有预防作用;
⑥对移植癌、癌的转移以及小鼠自发白血病有一定抑制作用,其作用较人参强而稳定,且能减轻抗癌药物的毒性。刺五加根的提取物尚具有中枢兴奋、抗应激、促进肝的再生能力、提高蛋白质的生物合成、降低基础代谢、促进性腺以及降低血压等作用。
实验表明,刺五加增加机体非特异性抵抗力的作用以刺五加甙e最强。本品长期服用未见任何不良反应。
牛磺酸是一种特殊的氨基酸,是人体必不可少的一种营养元素,有着平衡健康的奇妙功效。除了眼睛之外,牛磺酸还对其它器官有重要功效。例如,经过研究证实,人体心脏中牛磺酸含量最高。牛磺酸是通过保护心肌而增强心脏功能的。当心肌细胞中钙离子流入量过高时,就会引发冠心病。牛磺酸可以调整心肌细胞中钙离子的量,维持其平衡,实现强心。牛磺酸与心脏的关系已成为全世界重点研究的课题之一。此外,牛磺酸对肺、肝脏、胃肠等都有保护作用。
在日常生活方面,牛磺酸最显著的作用就在于增强免疫力和抗疲劳。牛磺酸可以结合白细胞中的次氯酸并生成无毒性物质,降低次氯酸对白细胞自身的破坏,从而提高人体免疫力。同时,牛磺酸能维持心脏功能,使血液循环正常化,从而消除疲劳生成物,使肌体能有效地产生能量。体内保持恒定的牛磺酸,便能有效地消除疲劳,这是维持人体健康的重要因素。
发明内容
本发明的目的在于提供一种耐缺氧抗疲劳的保健食品的配方及其制备方法。本发明所含的主要活性成分有刺五加提取物、牛磺酸和维生素。本发明中的维生素包括所有已知的维生素,可单一使用,也可组合使用;优选组合使用维生素B1、维生素B2和维生素B6。
本发明所含的各活性组分之间可以按任意比例组合使用;优选的活性成分的组成为每单位制剂含刺五加提取物100mg、牛磺酸200mg、维生素B1 0.06mg、维生素B2 0.06mg和维生素B6 0.06mg。
本发明的保健食品可以制成颗粒剂、胶囊,也可以压成各种片剂(包括普通型片剂/分散片、咀嚼片、口含片、口腔崩解片和泡腾片等片剂形式)。处方中除活性成分外,还有填充剂、崩解剂、润滑剂等辅料,根据情况还可以添加矫味剂、助流剂、粘合剂、泡腾剂或包衣材料。
本发明的保健食品的处方组成为:活性成分(10-90)%,粘合剂(0-5)%,填充剂(10-80)%,崩解剂(0.1-35)%,矫味剂(0-40)%,包衣材料(0-40)%,泡腾剂(0-30)%,助流剂(0-5)%,润滑剂(0-3)%。
本发明的保健食品的各种辅料的选择种类如下:
粘合剂包括但不仅限于淀粉、预胶化淀粉、糊精、麦芽糖糊精、蔗糖、阿拉伯胶、明胶、甲基纤维素、羧甲基纤维素、乙基纤维素、聚乙烯醇、聚乙二醇、聚乙烯吡咯烷酮(PVP)、海藻酸及海藻酸盐、黄原胶、羟丙基纤维素和羟丙基甲基纤维素(HPMC),可单独使用,也可组合使用。
填充剂包括但不仅限于甘露醇(粒状或粉状)、木糖醇、山梨醇、麦芽糖、赤蘚醇、微晶纤维素、PROSOLV SMCC、聚合糖(EMDEX)、偶合糖、葡萄糖、乳糖、蔗糖、糊精和淀粉等,可以单独使用,也可以组合应用。
崩解剂包括但不仅限于微晶纤维素、PROSOLV SMCC、交联聚乙烯吡咯烷酮(PVPP)、羧甲基淀粉钠(CMS-Na)、低取代羟丙基甲基纤维素(L-HPC)、交联羧甲基纤维素钠(CCNa)和大豆多糖(EMCOSOY)等,可单独使用,也可组合使用。
矫味剂包括但不仅限于甘露醇、木糖醇、甜菊甙、乳糖、果糖、蔗糖、蛋白糖、麦芽糖醇、甘草甜素、环己氨基磺酸钠、明胶、阿斯巴甜、香蕉香精、菠萝香精、香兰素、香橙香精、桔子香精、薄荷香精、人参香精、草莓香精、枸橼酸、柠檬酸等,可单独使用,也可组合使用。
包衣材料包括但不仅限于市售包衣预混剂、海藻酸盐、壳聚糖、羧甲基纤维素盐、醋酸纤维素酞酸酯、乙基纤维素、甲基纤维素、羟丙基纤维素、羟丙基甲基纤维素、丙烯酸树脂类(国产丙烯酸树脂I、II、III、IV,Eudragit系列)、聚乙烯醇、聚乙烯吡咯烷酮、聚乙二醇等,可单独使用,也可组合使用;可添加相应的增塑剂,也可添加色素和色淀等。
助流剂包括但不仅限于微粉硅胶、滑石粉、Cab-O-sil、瓵erosil、水合硅铝酸钠等,可单独使用,也可组合使用。
润滑剂包括但不仅限于硬脂酸镁、硬脂酸钙、硬脂酸锌、单硬脂酸甘油脂、聚乙二醇、氢化植物油、硬脂富马酸钠、聚氧乙烯单硬脂酸酯、单月桂蔗糖酸酯、月桂醇硫酸钠、月桂醇硫酸镁、十二烷基硫酸镁和滑石粉等,可单独使用,也可组合使用。
泡腾剂包括但不仅限于苹果酸、柠檬酸或富马酸与碳酸氢钠或碳酸钠的混合物。
本发明的另一目的将本发明的保健食品的任一项的制剂形式应用于哺乳动物和人缓解疲劳及提高他们的耐缺氧能力等方面。
具体实施例
下列实施例是为了更好地描述本发明,而不是限制本发明。
实施例一普通包衣片
一.处方
1.原料刺五加提取物100.0g;
牛磺酸200.0g;
维生素B1 0.06g;
维生素B2 0.06g;
维生素B6 0.06g;
2.填充剂微晶纤维素200.0g;
淀粉300.0g;
3.崩解剂羧甲基淀粉钠39.82g;
4.润滑剂硬脂酸镁10.0g;
5.包衣材料薄膜包衣预混剂10.0g。
共制成1000片。
二.制备方法
1)将牛磺酸、刺五加提取物和维生素B1、B2及B6分别过100目筛,备用;
2)将微晶纤维素和淀粉分别过80目筛,备用;
3)将步骤1)和步骤2)的物料按处方量混合均匀,备用;
4)将步骤3)的物料干法制粒,过26目筛整粒,备用;
5)加入处方量的羧甲基淀粉钠和硬脂酸镁,混匀;
6)中间体含量检测,确定片重后,送入压片机压片,硬度控制在80~100牛顿;
7)将素片包衣,即得。
实施例二胶囊
一.处方
1.原料刺五加提取物100.0g;
牛磺酸200.0g;
维生素B1 0.06g;
维生素B2 0.06g;
维生素B6 0.06g;
2.填充剂微晶纤维素91.82g;
2粘合剂羟丙基甲基纤维素4.0g;
4.助流剂微粉硅胶4.0g;
共制成1000粒胶囊。
二.制备方法
1)将牛磺酸、刺五加提取物和维生素B1、B2及B6分别过100目筛,备用;
2)将微晶纤维素和羟丙基甲基纤维素分别过80目筛,备用;
3)将步骤1)和步骤2)的物料按处方量混合均匀,备用;
4)将步骤3)的物料置于高速搅拌混合机中,以75%乙醇溶液为粘合剂制粒,过20目筛整粒,干燥;
5)加入处方量的微粉硅胶,混匀;
6)装胶囊,即得。
实施例三颗粒剂
一.处方
1.原料刺五加提取物100.0g;
牛磺酸200.0g;
维生素B1 0.06g;
维生素B2 0.06g;
维生素B6 0.06g;
2.填充剂微晶纤维素200.0g;
甘露醇434.82g;
蔗糖粉400.0g;
3.崩解剂大豆多糖150.0g;
4.助流剂微粉硅胶15.0g;
共制成1000小袋。
二.制备方法
1)将牛磺酸、刺五加提取物和维生素B1、B2及B6分别过100目筛,备用;
2)将微晶纤维素、甘露醇和蔗糖粉分别过80目筛,备用;
3)将步骤1)和步骤2)的物料按处方量混合均匀,备用;
4)将步骤3)的物料以50%乙醇溶液为润湿剂湿法制粒,在挤出机上过35目筛,整粒,干燥后备用;
5)加入处方量的微粉硅胶,混匀;
6)中间体含量检测,装袋,即得。
实施例四咀嚼片
一.处方
1.原料刺五加提取物100.0g;
牛磺酸200.0g;
维生素B1 0.06g;
维生素B2 0.06g;
维生素B6 0.06g;
2.填充剂聚合糖440.0g;
微晶纤维素80.0g;
3.粘合剂羟丙基甲基纤维素3.82g;
4.助流剂微粉硅胶8.0g;
5.矫味剂阿斯巴甜5.0g;
人参香精5.0g;
6.润滑剂硬脂酸镁8.0g。
共制成1000片。
二.制备方法
1)将牛磺酸、刺五加提取物和维生素B1、B2及B6分别过100目筛,备用;
2)将微晶纤维素、阿斯巴甜、人参香精和羟丙基甲基纤维素过80目筛,备用;
3)将步骤1)和步骤2)的物料按处方量混合均匀,备用;
4)将步骤3)的物料以50%的乙醇溶液为润湿剂制粒,过26目筛整粒,备用;
5)加入处方量的聚合糖、微粉硅胶和硬脂酸镁,混匀;
6)中间体含量检测,确定片重后,送入压片机压片,硬度控制在80~100牛顿,即得。
实施例五口含片
一.处方
1.原料刺五加提取物100.0g;
牛磺酸200.0g;
维生素B1 0.06g;
维生素B2 0.06g;
维生素B6 0.06g;
2.填充剂甘露醇(粒状)520.0g;
3.粘合剂羟丙基甲基纤维素3.82g;
4.助流剂微粉硅胶8.0g;
5.矫味剂阿斯巴甜5.0g;
薄荷香精5.0g;
6.润滑剂硬脂酸镁8.0g。
共制成1000片。
二.制备方法
1)将羟丙基甲基纤维素(3厘泊)用50%的乙醇溶液溶解,备用;
2)将阿斯巴甜混悬在上述溶液中,备用;
3)将牛磺酸、刺五加提取物和维生素B1、B2及B6分别过100目筛,置流化床中,用步骤2)的混悬液顶喷制粒,干燥;
4)将步骤3)的物料和处方量的薄荷香精、甘露醇、微粉硅胶和硬脂酸镁,混匀;
5)中间体含量检测,确定片重后,送入压片机压片,硬度控制在80~100牛顿,即得。
实施例六口腔崩解片
一.处方
1.原料刺五加提取物100.0g;
牛磺酸200.0g;
维生素B1 0.06g;
维生素B2 0.06g;
维生素B6 0.06g;
2.包衣材料Eudragit E100 36.0g;
Eudragit NE30D 30.0g;
3.填充剂甘露醇(粒状)410.82g;
4.崩解剂交联聚乙烯吡咯烷酮48.0g;
低取代羟丙基纤维素20.0g;
5.矫味剂阿斯巴甜5.0g;
薄荷香精5.0g;
6.助流剂微粉硅胶8.0g;
7.润滑剂硬脂酸镁8.0g。
共制成1000片。
二.制备方法
1)将Eudragit E100和Eudragit NE30D用适量的95%的乙醇溶液溶解,备用;
2)将阿斯巴甜混悬在上述溶液中,备用;
3)将牛磺酸、刺五加提取物和维生素B1、B2及B6分别过100目筛,置流化床中,用步骤2)的混悬液底喷包衣,干燥;
4)将步骤3)的物料和处方量的交联聚乙烯吡咯烷酮、低取代羟丙基纤维素、薄荷香精、甘露醇、微粉硅胶和硬脂酸镁,混匀;
5)中间体含量检测,确定片重后,送入压片机压片,硬度控制在15~35牛顿,即得。
实施例七分散片
一.处方
1.原料刺五加提取物100.0g;
牛磺酸200.0g;
维生素B1 0.06g;
维生素B2 0.06g;
维生素B6 0.06g;
2.包衣材料羟丙基甲基纤维素(3厘泊)60.0g;
3.填充剂甘露醇(粒状)399.82g;
微晶纤维素100.0g;
4.崩解剂交联聚乙烯吡咯烷酮60.0g;
低取代羟丙基纤维素40.0g;
5.矫味剂甜菊甙20.0g;
6.助流剂微粉硅胶10.0g;
7.润滑剂硬脂酸镁10.0g。
共制成1000片。
二.制备方法
1)将羟丙基甲基纤维素用适量的纯水溶液溶解,备用;
2)将甜菊甙混悬在上述溶液中,备用;
3)将低取代羟丙基纤维素、牛磺酸、刺五加提取物和维生素B1、B2及B6 100目筛,混匀,置流化床中,用步骤2)的混悬液底喷包衣,干燥;
4)将步骤3)的物料和处方量的微晶纤维素、交联聚乙烯吡咯烷酮、甘露醇、微粉硅胶和硬脂酸镁,混匀;
5)中间体含量检测,确定片重后,送入压片机压片,硬度控制在40~100牛顿,即得。
实施例八泡腾片
一.处方
1.原料刺五加提取物100.0g;
牛磺酸200.0g;
维生素B1 0.06g;
维生素B2 0.06g;
维生素B6 0.06g;
2.包衣材料Eudragit E100 36.0g;
3.填充剂聚合糖203.82g;
微晶纤维素100.0g;
5.矫味剂甜菊甙20.0g;
6.泡腾剂枸橼酸170.0g;
碳酸氢钠150.0g;
6.助流剂微粉硅胶10.0g;
7.润滑剂硬脂酸镁10.0g。
共制成1000片。
二.制备方法
1)将Eudragit E100用适量的95%的乙醇溶液溶解,备用;
2)将甜菊甙混悬在上述溶液中,备用;
3)将碳酸氢钠、牛磺酸、刺五加提取物和维生素B1、B2及B6 100目筛,混匀,置流化床中,用步骤2)的混悬液底喷包衣,干燥;
4)将步骤3)的物料和处方量的微晶纤维素、枸橼酸、聚合糖、微粉硅胶和硬脂酸镁,混匀;
5)中间体含量检测,确定片重后压片,硬度控制在50~100牛顿,即得。
Claims (8)
1.一种具有耐缺氧抗疲劳功效的保健食品,其中,刺五加提取物100.0g,牛磺酸200.0g,维生素B1 0.06g,维生素B2 0.06g,维生素B6 0.06g,微晶纤维素200.0g,淀粉300.0g,羧甲基淀粉钠39.82g,硬脂酸镁10.0g,薄膜包衣预混剂10.0g,按照如下方法制成1000片普通包衣片:1)将牛磺酸、刺五加提取物和维生素B1、B2及B6分别过100目筛,备用;2)将微晶纤维素和淀粉分别过80目筛,备用;3)将步骤1)和步骤2)的物料按处方量混合均匀,备用;4)将步骤3)的物料干法制粒,过26目筛整粒,备用;5)步骤4)所得颗粒中加入处方量的羧甲基淀粉钠和硬脂酸镁,混匀;6)步骤5)所得物料经中间体含量检测,确定片重后,送入压片机压片,硬度控制在80~100牛顿;7)将步骤6)所得的素片包衣,即得。
2.一种具有耐缺氧抗疲劳功效的保健食品,其中,刺五加提取物100.0g,牛磺酸200.0g,维生素B1 0.06g,维生素B2 0.06g,维生素B6 0.06g,微晶纤维素91.82g,羟丙基甲基纤维素4.0g,微粉硅胶4.0g,按照如下方法制成1000粒胶囊:1)将牛磺酸、刺五加提取物和维生素B1、B2及B6分别过100目筛,备用;2)将微晶纤维素和羟丙基甲基纤维素分别过80目筛,备用;3)将步骤1)和步骤2)的物料按处方量混合均匀,备用;4)将步骤3)的物料置于高速搅拌混合机中,以75%乙醇溶液为粘合剂制粒,过20目筛整粒,干燥;5)步骤4)所得颗粒中加入处方量的微粉硅胶,混匀,装胶囊,即得。
3.一种具有耐缺氧抗疲劳功效的保健食品,其中,刺五加提取物100.0g,牛磺酸200.0g,维生素B1 0.06g,维生素B2 0.06g,维生素B6 0.06g,微晶纤维素200.0g,甘露醇434.82g,蔗糖粉400.0g,大豆多糖150.0g,微粉硅胶15.0g,按照如下方法制成1000袋颗粒剂:1)将牛磺酸、刺五加提取物和维生素B1、B2及B6分别过100目筛,备用;2)将微晶纤维素、甘露醇和蔗糖粉分别过80目筛,备用;3)将步骤1)和步骤2)的物料按处方量混合均匀,备用;4)将步骤3)的物料以50%乙醇溶液为润湿剂湿法制粒,在挤出机上过35目筛,整粒,干燥后备用;5)步骤4)所得颗粒中加入处方量的微粉硅胶,混匀;6)步骤5)所得物料经中间体含量检测,装袋,即得。
4.一种具有耐缺氧抗疲劳功效的保健食品,其中,刺五加提取物100.0g,牛磺酸200.0g,维生素B1 0.06g,维生素B2 0.06g,维生素B6 0.06g,聚合糖440.0g,微晶纤维素80.0g,羟丙基甲基纤维素3.82g,微粉硅胶8.0g,阿斯巴甜5.0g,人参香精5.0g,硬脂酸镁8.0g,按照如下方法制成1000片咀嚼片:1)将牛磺酸、刺五加提取物和维生素B1、B2及B6分别过100目筛,备用;2)将微晶纤维素、阿斯巴甜、人参香精和羟丙基甲基纤维素过80目筛,备用;3)将步骤1)和步骤2)的物料按处方量混合均匀,备用;4)将步骤3)的物料以50%的乙醇溶液为润湿剂制粒,过26目筛整粒,备用;5)步骤4)所得颗粒中加入处方量的聚合糖、微粉硅胶和硬脂酸镁,混匀;6)步骤5)所得物料经中间体含量检测,确定片重后,送入压片机压片,硬度控制在80~100牛顿,即得。
5.一种具有耐缺氧抗疲劳功效的保健食品,其中,刺五加提取物100.0g,牛磺酸200.0g,维生素B1 0.06g,维生素B2 0.06g,维生素B6 0.06g,粒状甘露醇520.0g,羟丙基甲基纤维素3.82g,微粉硅胶8.0g,阿斯巴甜5.0g,薄荷香精5.0g,硬脂酸镁8.0g,按照如下方法制成1000片口含片:1)将羟丙基甲基纤维素用50%的乙醇溶液溶解,备用;2)将阿斯巴甜混悬在步骤1)所得的溶液中,备用;3)将牛磺酸、刺五加提取物和维生素B1、B2及B6分别过100目筛,置流化床中,用步骤2)的混悬液顶喷制粒,干燥;4)将步骤3)的物料和处方量的薄荷香精、甘露醇、微粉硅胶和硬脂酸镁,混匀;5)步骤4)所得物料经中间体含量检测,确定片重后,送入压片机压片,硬度控制在80~100牛顿,即得。
6.一种具有耐缺氧抗疲劳功效的保健食品,其中,刺五加提取物100.0g,牛磺酸200.0g,维生素B1 0.06g,维生素B2 0.06g,维生素B6 0.06g,EudragitE100 36.0g,Eudragit NE30D 30.0g,粒状甘露醇410.82g,交联聚乙烯吡咯烷酮48.0g,低取代羟丙基纤维素20.0g,阿斯巴甜5.0g,薄荷香精5.0g,微粉硅胶8.0g,硬脂酸镁8.0g,按照如下方法制成1000片口腔崩解片:1)将Eudragit E100和Eudragit NE30D用适量的95%的乙醇溶液溶解,备用;2)将阿斯巴甜混悬在步骤1)所得的溶液中,备用;3)将牛磺酸、刺五加提取物和维生素B1、B2及B6分别过100目筛,置流化床中,用步骤2)的混悬液底喷包衣,干燥;4)将步骤3)的物料和处方量的交联聚乙烯吡咯烷酮、低取代羟丙基纤维素、薄荷香精、甘露醇、微粉硅胶和硬脂酸镁,混匀;5)步骤4)所得物料经中间体含量检测,确定片重后,送入压片机压片,硬度控制在15~35牛顿,即得。
7.一种具有耐缺氧抗疲劳功效的保健食品,其中,刺五加提取物100.0g,牛磺酸200.0g,维生素B1 0.06g,维生素B2 0.06g,维生素B6 0.06g,羟丙基甲基纤维素60.0g,粒状甘露醇399.82g,微晶纤维素100.0g,交联聚乙烯吡咯烷酮60.0g,低取代羟丙基纤维素40.0g,甜菊甙20.0g,微粉硅胶10.0g,硬脂酸镁10.0g,按照如下方法制成1000片分散片:1)将羟丙基甲基纤维素用适量的纯水溶液溶解,备用;2)将甜菊甙混悬在步骤1)所得的溶液中,备用;3)将低取代羟丙基纤维素、牛磺酸、刺五加提取物和维生素B1、B2及B6 100过目筛,混匀,置流化床中,用步骤2)的混悬液底喷包衣,干燥;4)将步骤3)的物料和处方量的微晶纤维素、交联聚乙烯吡咯烷酮、甘露醇、微粉硅胶和硬脂酸镁混匀;5)步骤4)所得物料经中间体含量检测,确定片重后,送入压片机压片,硬度控制在40~100牛顿,即得。
8.一种具有耐缺氧抗疲劳功效的保健食品,其中,刺五加提取物100.0g,牛磺酸200.0g,维生素B1 0.06g,维生素B2 0.06g,维生素B6 0.06g,EudragitE100 36.0g,聚合糖203.82g,微晶纤维素100.0g,甜菊甙20.0g,枸橼酸170.0g,碳酸氢钠150.0g,微粉硅胶10.0g,硬脂酸镁10.0g,按照如下方法制成1000片泡腾片:1)将Eudragit E100用适量的95%的乙醇溶液溶解,备用;2)将甜菊甙混悬在步骤1)溶液中,备用;3)将碳酸氢钠、牛磺酸、刺五加提取物和维生素B1、B2及B6过100目筛,混匀,置流化床中,用步骤2)的混悬液底喷包衣,干燥;4)将步骤3)的物料和处方量的微晶纤维素、枸橼酸、聚合糖、微粉硅胶和硬脂酸镁,混匀;5)步骤4)所得物料经中间体含量检测,确定片重后压片,硬度控制在50~100牛顿,即得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200510002275XA CN100438778C (zh) | 2005-01-20 | 2005-01-20 | 一种耐缺氧抗疲劳的保健食品及其制备工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200510002275XA CN100438778C (zh) | 2005-01-20 | 2005-01-20 | 一种耐缺氧抗疲劳的保健食品及其制备工艺 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1631247A CN1631247A (zh) | 2005-06-29 |
CN100438778C true CN100438778C (zh) | 2008-12-03 |
Family
ID=34852947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB200510002275XA Expired - Fee Related CN100438778C (zh) | 2005-01-20 | 2005-01-20 | 一种耐缺氧抗疲劳的保健食品及其制备工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100438778C (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101336723B (zh) * | 2008-07-30 | 2012-07-18 | 广州蓝钥匙海洋生物工程有限公司 | 一种用于缓解体力疲劳的保健食品 |
CN102389116B (zh) * | 2011-11-23 | 2013-05-15 | 武汉工程大学 | 一种能够缓解体力疲劳的泡腾片及其制备工艺 |
CN102579686B (zh) * | 2011-12-06 | 2014-05-28 | 西安泰科迈医药科技有限公司 | 一种中药含片及其制备方法 |
CN102552247B (zh) * | 2012-03-07 | 2014-05-28 | 常州市第四制药厂有限公司 | 一种维生素c的组合物及其制备方法 |
CN102599406A (zh) * | 2012-03-15 | 2012-07-25 | 河南省南街村(集团)有限公司 | 一种二元复合多肽咀嚼片的生产工艺 |
CN102599405A (zh) * | 2012-03-15 | 2012-07-25 | 河南省南街村(集团)有限公司 | 一种二元复合多肽咀嚼片 |
CN103800562A (zh) * | 2012-11-06 | 2014-05-21 | 张立中 | 一种清新口气、提高精神、缓解疲劳的制剂 |
CN103039985A (zh) * | 2012-12-28 | 2013-04-17 | 杨石 | 一种具有缓解体力疲劳功能的保健食品 |
CN104000181A (zh) * | 2013-02-27 | 2014-08-27 | 北京宝德润生医药科技发展有限公司 | 一种用于缓解体力疲劳的组合物及其制备方法 |
CN103704711B (zh) * | 2013-12-31 | 2014-12-10 | 程刚 | 一种具有抗疲劳保健功能冲剂 |
CN104738450B (zh) * | 2015-03-09 | 2017-12-01 | 沈阳农业大学 | 用无梗五加果粉制备泡腾片的方法 |
CN107149077A (zh) * | 2016-03-02 | 2017-09-12 | 广州宏韵医药科技股份有限公司 | 一种跑步后泡腾片及其制备方法 |
CN114009769B (zh) * | 2021-11-25 | 2023-06-30 | 广州白云山汉方现代药业有限公司 | 一种应用于脱油蛋黄粉复配片剂的复配填充剂 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1096646A (zh) * | 1993-06-21 | 1994-12-28 | 徐兴华 | 富矿多维强化营养粉(糊) |
CN1299621A (zh) * | 1999-12-14 | 2001-06-20 | 焦柏忠 | 刺五加保健饮品及制作方法 |
CN1483355A (zh) * | 2002-09-16 | 2004-03-24 | 岚 高 | 抗疲劳饮料配方 |
-
2005
- 2005-01-20 CN CNB200510002275XA patent/CN100438778C/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1096646A (zh) * | 1993-06-21 | 1994-12-28 | 徐兴华 | 富矿多维强化营养粉(糊) |
CN1299621A (zh) * | 1999-12-14 | 2001-06-20 | 焦柏忠 | 刺五加保健饮品及制作方法 |
CN1483355A (zh) * | 2002-09-16 | 2004-03-24 | 岚 高 | 抗疲劳饮料配方 |
Non-Patent Citations (2)
Title |
---|
膳食补充片剂(胶囊)的生产. 左曙辉,孙程.中国食品添加剂,第2期. 2004 |
膳食补充片剂(胶囊)的生产. 左曙辉,孙程.中国食品添加剂,第2期. 2004 * |
Also Published As
Publication number | Publication date |
---|---|
CN1631247A (zh) | 2005-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100438778C (zh) | 一种耐缺氧抗疲劳的保健食品及其制备工艺 | |
US20090028896A1 (en) | Compositions and method for weight loss | |
CN102406679B (zh) | 一种中药西洋参口含片 | |
WO2012034498A1 (zh) | 一种增强机体免疫力并能控制糖尿病的产品 | |
CN101890040A (zh) | 一种具有抗疲劳作用的组合物及其应用 | |
CN1327838C (zh) | 维生素c口腔崩解片及其制备方法 | |
CN1561980A (zh) | 盐酸二甲双胍肠溶缓释制剂及其制备方法 | |
CN101822672A (zh) | 一种含二甲双胍和瑞格列奈的复方及其制备方法和用途 | |
CN104489681A (zh) | 一种具有增强免疫力功能的组合物、保健品及其制备方法 | |
CN101670056B (zh) | 一种治疗恶性肿瘤的药物 | |
WO2021109511A1 (zh) | 一种抗疲劳的组合物及其制备方法 | |
CN102406690A (zh) | 一种中药绞股兰口含片 | |
CN105343056A (zh) | 一种治疗或预防肥胖型高血压的口服药物组合物及其用途 | |
WO2004096252A1 (en) | Compositions and methods for weight loss | |
CN102872062A (zh) | 一种治疗或预防肥胖症以及代谢综合症的药物组合物 | |
KR20220062386A (ko) | 우울한 기분 조절 작용이 있는 한약 추출물 조성물 및 그 제조 방법과 한약 제제 | |
CN104000181A (zh) | 一种用于缓解体力疲劳的组合物及其制备方法 | |
CN110881555A (zh) | 一种具有双降作用的分散糖果片 | |
CN101828703B (zh) | 一种增强机体免疫力并能改善睡眠质量的产品及制备方法 | |
CN101756993A (zh) | 用于减肥或治疗代谢综合征的药物组合物 | |
CN101589806A (zh) | 一种富含膳食纤维和聚乙二醇的固体低能量食品及其制备方法 | |
CN100446759C (zh) | 一种天麻素口腔崩解片及其制备方法 | |
CN110269897A (zh) | 一种抗疲劳和改善睡眠的组合物及其用途 | |
CN1263457C (zh) | 绞股蓝总皂苷口腔崩解片及其制备工艺 | |
CN1267094C (zh) | 红花黄色素口腔崩解片及其制备工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 100083 Haidian District, Xueyuan Road, No. 30, A building, room No. 15, room, room 15 Patentee after: COSCI MED-TECH Co.,Ltd. Address before: 100080, Haidian District satellite building, No. 63, Zhichun Road, Beijing, room 1410, Beijing Patentee before: COSCI MED-TECH Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081203 |